81118. Adulteration of strychnine sulfate tablets, sodium salicylate tablets, 
fluidextract of ipecac, four chlorides elixir, and tincture of belladonna 
leaves; adulteration and misbranding of hydrangea compound lithiated. 
U.   S.   v.   Flint,   Eaton  &   Co.    Plea  of   nolo   contendere.    Fine,   $175.
(F.   &  D.   No.   31333.    Sample   Nos.   15604-A,   17038-A,   17041-A,   17046-A, 
17050-A, 17107-A.)
The strychnine sulfate tablets, sodium salicylate tablets, and hydrangea com- 
pound lithiated fell below the standard declared on their labels; and the fluid- 
extract of ipecac, four chlorides elixir, and tincture of belladonna leaves differed 
from the standard prescribed in the United States Pharmacopoeia or the National 
Formulary.
On February 26, 1934, the United States attorney for the Southern District 
of Illinois filed an information against Flint, Eaton & Co., a corporation, Decatur, 
HI., alleging shipment on or about June 4, August 22, and August 23, 1932, from 
the State of Illinois into the States of Iowa and Missouri of quantities of the 
above-named pharmaceuticals which were adulterated and one of which was also 
misbranded.
The strychnine sulfate tablets were alleged to be adulterated in that their 
strength and purity fell below the professed standard and quality under which 
they were sold in that each of the tablets was represented to contain %o grain of 
strychnine sulfate; whereas each of the tablets contained strychnine sulfate in 
excess of the amount declared, namely, 0.0197 grain (%o grain) of strychnine 
sulfate.
The sodium salicylate tablets were alleged to be adulterated in that their 
strength and purity fell below the professed standard and quality under which 
they were sold in that each tablet was represented to contain 5 grains of 
sodium salicylate; whereas each tablet contained less than so represented, 
namely, not more than 4.02 grains of sodium salicylate.
The hydrangea compound lithiated was alleged to be adulterated in that its 
strength and purity fell below the professed standard and quality under which 
it was sold in that each fluid dram of the article was represented to contain 
4 grains of lithium salicylate; whereas each fluid dram thereof contained more 
than so represented, namely not less than 4.94 grains of lithium salicylate. 
It was alleged to be misbranded in that the statement "Each fluid dram con- 
tains * * * Lith. Salicylate 4 grains," borne on the bottle label, was false 
and misleading.
The fluidextract of ipecac was alleged to be adulterated in that it was sold 
under and by a name recognized in the United States Pharmacopoeia, but 
differed from the standard of strength, quality, and purity as determined by 
the test laid down in the pharmacopoeia official at the time of investigation 
since it yielded less than 1.35 grams, namely, not more than 0.78 gram of the 
ether-soluble alkaloids of ipecac per 100 cubic centimeters; whereas the pharma- 
copoeia provides that fluidextract of ipecac shall yield not less than 1.35 grams 
of the ether-soluble alkaloids of ipecac per 100 cubic centimeters; and the 
standard of strength, quality, and purity of the article was not contained in 
the labeling thereof.
The four chlorides elixir was alleged to be adulterated in that it was sold 
under a name recognized in the National Formulary, but differed from the 
standard of strength, quality, and purity as determined by the test laid down in 
the Formulary official at the time of investigation since it'contained in each 
1,000 'cubic centimeters more than 16.5 cubic centimeters, namely, not less 
than 26 cubic centimeters, of arsenous acid; whereas the National Formulary
provides that elixir of four chlorides shall contain not more than 16.5 cubic 
centimeters of arsenous acid in each 1,000 cubic centimeters; and the standard 
of strength, quality, and purity of the article was not declared on its label. 
It was alleged to be adulterated further in that its strength and purity fell 
below the professed standard and quality under which it was sold in that each 
fluid ounce was represented to contain % grain of arsenic chloride; whereas 
each fluid ounce contained more than so represented, namely, not less'than 
% grain of arsenic chloride.
The tincture of belladonna leaves was alleged to be adulterated in that it 
was sold under and by a name recognized in the United States Pharmacopoeia, 
but differed from the standard of strength, quality, and purity as determined by 
the test laid down in the pharmacopoeia official at the time of investigation 
since it yielded less than 0.027 gram, namely, not more than 0.0198 gram of 
the alkaloids of belladonna leaves per 100 cubic centimeters; whereas the 
pharmacopoeia provides that tincture of belladonna yields not less than 0.027 
gram of the alkaloids of belladonna leaves per 100 cubic centimeters; and the 
standard of strength, quality, and purity of the article was not declared on 
the container thereof. It was alleged to be adulterated further in that its 
strength and purity fell below the professed standard and quality under which 
it was sold, since it was represented to be tincture of belladonna leaves which 
conformed to the standard laid down in such compendium; whereas it did 
not conform to such standard.
On June 28, 1940, a plea of nolo contendere having been entered on behalf 
of the defendant, the court imposed a fine of $25 on each count in lieu of 
fine and costs, the total fine amounting to $175.